Beleave Completes First Harvest at Hamilton Facility Print E-mail
By GLOBE NEWSWIRE   
Thursday, 28 September 2017 02:00

TORONTO, Sept. 28, 2017 (GLOBE NEWSWIRE)

TORONTO, Sept. 28, 2017 (GLOBE NEWSWIRE) -- Beleave Inc. ("Beleave" or the "Company") (CSE:BE) (OTCQX:BLEVF) is pleased to announce that it has completed harvesting and drying its first two lots of cannabis at its Hamilton, Ontario facility; a process required by Health Canada prior to requesting a sales license. The Company will apply for a license to sell dried cannabis after it has received confirmation from a third-party laboratory that quality assurance testing results are compliant with the Access to Cannabis for Medical Purposes Regulations.

"We are extremely pleased with everything having gone according to what we expected. Furthermore, we have developed quite a bit of knowledge with respect to the strains we are cultivating, and are continually fine tuning our growing practices to optimize these strains for large scale commercial production," commented Beleave CEO, Roger Ferreira. "Our facility is now in full production, with plants at each stage of the growth cycle. We anticipate a quick turnaround time between crops moving forward."

About Beleave
Beleave Inc. is a biotech company and Beleave's wholly-owned subsidiary Beleave Kannabis Corp. (formerly First Access Medical Inc.) is a licensed producer pursuant to the ACMPR. Beleave's purpose-built facility is located near Hamilton, Ontario.

For further information please contact:

Sebastian de Kloet
Phone: (905) 979 - 5173      
Email: sebastian@beleave.com
beleave.com

Forward-Looking Statements 

This news release contains "forward-looking information" within the meaning of applicable securities law ("forward-looking statements"). The use of any of the words "plan", "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and other similar words, or statements that certain events or conditions "may" or "will" occur are intended to identify forward-looking information. These statements are only predictions. Although the Company believes that the expectations and assumptions on which the forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. These risks and uncertainties include, but are not limited to, the Company's ability to satisfy the conditions associated with its cultivation licence, the Company's ability to obtain a sales licence and the related timing considerations, the availability of further financing, consumer interest in its products, competition, regulation, operational and

technological risks, and anticipated and

Error. Page cannot be displayed. Please contact your service provider for more details. (17)

unanticipated costs and
delays. Since forward-looking information addresses future events and conditions, by its very nature it involves inherent risks and uncertainties. This information speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company's disclosure documents, which can be found under the Company's profile on www.sedar.com. 

Primary Logo




BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!
 

Newsletter

BMR:1